During this webinar, Dr. Yvan Caspar will describe in detail two complementary studies performed at the Centre Hospitalier Universitaire Grenoble Alpes (CHUGA) using the trio of cobas® eplex blood culture identification panels for detection of bloodstream infections caused by gram-negative, gram-positive, and fungal pathogens. First, he will discuss the results of a retrospective study that assessed the analytical performance of the cobas eplex BCID panels and the potential clinical outcomes based on these results.
For each positive blood culture included in the study, the patient’s health record was retrospectively reviewed by a clinical team to assess how the rapid detection of pathogens and antimicrobial resistance genes from positive blood cultures, using the cobas eplex BCID panels, would have potentially changed the management of patients with bloodstream infections.
Dr. Caspar will then highlight initial data that has been collected and analyzed from the HEMOFAST prospective randomized clinical trial, which is a clinical and medico-economic evaluation of the cobas eplex BCID panels for the diagnosis of bacteremia and fungemia compared to conventional microbiology. While the trial was still in progress, preliminary data was presented to provide a glimpse into the benefits of the cobas eplex BCID panels.
As the body of scientific literature for faster identification and management of bloodstream infections grows, the data generated at CHUGA continues to expand the evidence supporting the clinical utility of these technologies. The two studies being showcased in this webinar will provide a big-picture view of how the cobas eplex BCID panels are improving rapid blood culture diagnostics.
